Product Data Sheet

Product Name: AR-C 66096 tetrasodium salt
Cat. No.: GC12914

Chemical Properties

Cas. No.	145782-74-7		
SMILES	CCCSC1=NC(N)=C(N=CN2[C@@]3([H])[C@](O)([H])[C@@](O)([H])[C@@](O3)([H])COP([O-])(OP(C(F)(P([O-])([O-])=O)F)([O-])=O)=O)C2=N1.[Na+].[Na+].[Na+].[Na+]		
Formula	$C_{14}H_{18}F_2N_5Na_4O_{12}P_3S$	M.Wt	703.26
Solubility	<10mM in Water	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	AR-C 66096 tetrasodium salt		

Background

The platelet P2T receptor plays a major role in platelet aggregation, and its antagonists are suggested to have significant therapeutic potential as antithrombotic agents. AR-C 66096 is a novel, potent and selective antagonist at human platelet P2T-purinoceptors.

In vitro: In suspensions of human washed platelets, AR-C 66096 (1-100 nM) produced concentrationdependent rightward displacement of concentration-effect (E/[A]) curves obtained for ADP-induced platelet aggregation. The anti-aggregatory potency of AR-C 66096 was not influenced by increasing the incubation time from 2 to 15 min nor by inclusion of the P1-purinoceptor antagonist 8-sulphophenyltheophylline at a concentration (300 μM) [1].

In vivo: AR-C 66096 behaved as a weak (pA50 3.68) but full P2x-purinoceptor agonist in preparations of the isolated rabbit ear artery and as a weak, competitive antagonist (apparent pKB 4.71) at P2Y-purinoceptors in the isolated guinea-pig aorta, indicating a selectivity of at least 9000 fold for the Pzrsubtype. In the latter preparation, non-specific

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

relaxations were observed by concentrations of AR-C 66096 >10 μM [1].

Clinical trial: Up to now, AR-C 66096 is still in the preclinical development stage.

Reference:
[1] Humphries, R. G.; Tomlinson, W.; Ingall, A. H.; Cage, P. A.; Leff, P. FPL 66096: A Novel, Highly Potent and Selective Antagonist at Human Platelet P2T-purinoceptors. Br. J. Pharmacol. 1994, 113, 1057-1063.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA